The optimal platinum doublet regimen in elderly patients with non-small-cell lung cancer (NSCLC) is still uncertain. We conducted a randomized phase II study to compare the efficacy and safety of weekly paclitaxel combined with carboplatin with those of the standard schedule. Results: Eighty-two patients were enrolled. The ORR and median progression-free survival were 55% and 6.0 months for the weekly arm and 53% and 5.6 months for the standard arm. Grade 3/4 neutropenia and peripheral neuropathy were observed in 41% and 0% of the patients in the weekly arm and in 88% and 25% in the standard arm, respectively.
introduction
Lung cancer is the leading cause of cancer deaths in most of the developed countries. More than 80% of the patients with lung cancer have non-small-cell histology and 40% of the patients present at stage IIIB or stage IV of the disease at diagnosis [1, 2] . For these patients with advanced non-small-cell lung cancer (NSCLC), platinum-based combinations have been accepted as the standard of care on the basis of their survival benefit [3] [4] [5] . In particular, the combination of carboplatin and paclitaxel is the most commonly used regimen for the treatment of advanced NSCLC and has been selected as the reference arm in several phase III trials [6, 7] . With regard to the carboplatin and paclitaxel combination, peripheral neuropathy, myalgia, arthralgia, and myelosuppression are the major clinical conditions that distress patients and sometimes lead to treatment withdrawal. To minimize the occurrence of these toxic effects and to improve the tolerability of this regimen, weekly schedule of paclitaxel has been evaluated and found to be associated with a reduction in the treatment toxicity and feasible therapeutic indices for patients with advanced NSCLC although these studies mainly included younger patients and the benefit of such a regimen for elderly patients remains unknown [8] [9] [10] .
The benefit of platinum doublet chemotherapy for the elderly is still controversial. Some investigators recommend singleagent chemotherapy with new-generation chemotherapeutic agents such as vinorelbine or gemcitabine on the basis of the evidences from some phase III trials [11] [12] [13] ; on the other hand, others consider that platinum doublet chemotherapy is also acceptable for elderly patients, although the frequency and severity of toxic effects associated with the latter are generally high [14] . In this context, we previously conducted an elderly-specific phase II study of weekly paclitaxel combined with carboplatin, which demonstrated a reasonable response rate (45%) and less severe toxic effects (e.g. a grade 3 peripheral neuropathy rate of 3%) [15] . Next, we planned the current randomized phase II trial that involved weekly paclitaxel combined with carboplatin and compared it with standard triweekly regimen of paclitaxel combined with carboplatin for elderly patients with advanced NSCLC; this was done in order to select a proper regimen for future phase III studies that compare the efficacy of platinum doublet chemotherapy with that of single-agent chemotherapy.
patients and methods

selection of patients
Patients (age ‡70 years) with cytologically or histologically confirmed stage IIIB, stage IV, or postoperative recurrent NSCLC with measurable lesions who had never received chemotherapy or radiotherapy were enrolled in this study. Further, patients were also required to satisfy the following criteria: Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero to one, an estimated life expectancy exceeding 12 weeks, white blood cell (WBC) count of >4000/mm 3 (or a neutrophil count of >2000/mm 3 ), hemoglobin levels of >9.0 g/dl, platelet count of >100 000/mm 3 , serum total bilirubin level of <1.5 mg/dl, serum levels of aspartate aminotransferase and alanine aminotransferase <2.0· the institutional upper limit of the normal range, serum creatinine levels of <1.5 mg/dl, and pO 2 level of >60 mmHg. We excluded patients with symptomatic brain metastasis or severe comorbidities such as symptomatic cardiovascular disease, liver cirrhosis, radiographically obvious pulmonary fibrosis, acute peptic ulcer, uncontrolled diabetes, and peripheral neuropathy. The institutional review boards of all the nine hospitals approved this study, and a written informed consent was obtained from all the enrolled patients.
treatment schedule
The enrolled patients were stratified by clinical stage (IIIB, IV, or postoperative recurrence) or ECOG PS (0 or 1) at baseline and then randomly assigned to receive the weekly paclitaxel with carboplatin arm (W arm), in which 70 mg/m 2 paclitaxel was administered once a week on days neutropenia lasting 4 days, grade 2 or worse peripheral neuropathy, myalgia, or arthralgia, or grade 3 or worse non-hematological toxic effects other than nausea, vomiting, and appetite loss. Further, carboplatin was reduced to AUC 5.0 in both the arms when the platelet count decreased to <20 000/mm treatment assessment
Baseline assessment included a physical examination, complete blood counts (CBC) with differential and platelet count, hepatic and renal function tests, urine analysis, 12-lead electrocardiogram, and chest radiography. Tumor evaluation was carried out at the baseline by either a computed tomography (CT) scan or magnetic resonance imaging. During the study, the medical history and results of physical examination, weight, vital signs, ECOG PS, CBC, blood chemistry, and chest radiography were monitored on a weekly basis. Radiographic evaluation by CT scan was carried out at least every two cycles to assess the patient's response to the treatment. Unidirectional measurements were undertaken according to the RECIST criteria. The definitions of complete response (CR), partial response (PR), progressive disease (PD) and stable disease (SD) are as follows: CR, disappearance of all target lesions; PR, at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters; PD, at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study or the appearance of one or more new lesions; SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. The confirmation of CR and PR required response duration of ‡4 weeks, while the confirmation of stable disease required response duration of ‡6 weeks after the initiation of the treatment. Toxic effects were assessed according to the National Cancer Institute-Common Toxicity Criteria version 2.0.
statistical analysis
The primary end point of this study was the overall response rate (ORR), and the secondary end points were the progression-free survival (PFS), overall survival, and toxicity profile. The sample size was calculated independently for each arm as follows. Assuming that an ORR of 40% in eligible patients would indicate potential usefulness, while an ORR of 20% would constitute the lower limit of interest, with a = 0.05 and b = 0.2, the estimated accrual was 36 in each arm. Fisher's exact test was used to estimate the correlation among the different variables of the two arms. The estimation of survival was carried out using the Kaplan-Meier method and the log-rank test.
results
patient characteristics
From November 2004 to June 2007, 82 patients were enrolled from nine institutions in this study ( Table 1 ). The median age of the patients at the time of enrollment was 75 years (range 70-87 years); 57% of the patients were ‡75 years and 15% of the patients were ‡80 years. Of the 82 patients, 69 (84%) were male and 40 (49%) had PS of one. Adenocarcinoma and squamous cell carcinoma were the most common histological types and were observed in 47% and 41% of the patients, respectively. There were 26 (31%) patients with stage IIIB, 47 (57%) with stage IV, and 9 (11%) with postoperative recurrence. There was no statistical difference in the patient characteristics of the two arms. The median number of cycles of the treatment was three cycles (range 1-6) in each arm, and original article Annals of Oncology 75% of the patients underwent three or more cycles in each arm. In the weekly arm, 42 patients received 139 cycles in total. Among 417 planned administrations of paclitaxel, 31 were skipped mainly because of temporary toxicity and 93% of planned doses were actually administered.
response and survival
The ORR (CR + PR) observed for the W and S arms were 55% [95% confidence interval (CI) 40% to 70%] and 53% (95% CI 38% to 68%), respectively ( Table 2 ). There was no statistical difference in the response of the patients in the two arms. One patient in the W arm could not be evaluated for the response because the patient died due to treatment-related effects before the first evaluation of the efficacy. The median PFS and median survival time (MST) were 6.0 and 14.7 months for the patients of the W arm and 5.6 and 15.5 months for the patients of the S arm, respectively (Figure 1 ).
toxicity
The treatment-related grade 2 or worse toxic effects observed in this study are summarized in Table 3 . Neutropenia was the most common hematological toxicity in both arms, and grade 3 or 4 neutropenia was observed in 41% and 88% of the patients in the W and S arms, respectively (P < 0.0001). Febrile neutropenia was observed in 2% and 10% of the patients in the W and S arms, respectively. Grade 3 peripheral neuropathy was observed in 0% and 25% of the patients in the W and S arms, respectively (P = 0.018). Myalgia and arthralgia also tended to be severe in the patients of the S arm. Although other non-hematological toxic effects observed were almost moderate and manageable, there was one treatment-related death in the W arm owing to drug-induced interstitial lung disease.
discussion
Although the number of elderly patients with advanced NSCLC has been increasing, the standard of care for such patients remains controversial. Randomized phase III studies of singleagent chemotherapy with drugs such as vinorelbine or gemcitabine demonstrated that the survival benefit for elderly NSCLC patients treated with this modality was higher than that 
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of the best supportive treatment [11, 12] . In addition, a recent Japanese study has indicated that docetaxel monotherapy is also suitable for elderly NSCLC patients, although the extremely high efficacy (an MST of 14.3 months) should be reexamined by another confirmatory study [13] . On the other hand, there has been no randomized study of platinum doublet chemotherapy specifically targeting the elderly population. Some retrospective analyses conducted on the subgroup of the elderly from several trials without an upper age limit have documented the benefits of platinum-based combination chemotherapy in those patients with good PS [14] . However, the percentage of the elderly population enrolled in those trials was only 30%-40%, which is much lesser than that of general practice, indicating that a selection bias clearly exists in the enrollment of elderly patients into such clinical trials in which there is no upper limit for the age of the patients. Moreover, even in those selected elderly patients with good PS, toxic effects tend to be more severe than those in younger patients, thus clearly indicating the need for elderly-specific clinical trials [16] . In this study, the patients of both the W and the S arms met the primary end point, indicating that the combination treatment of paclitaxel and carboplatin with each schedule is effective for elderly NSCLC patients. The survival data (PFS and MST) were also similar between the two arms, both of which are comparable to the results of previous trials of platinum doublet chemotherapy conducted in younger patients [3] [4] [5] [6] [7] . The tendency of efficacy and safety results of our study was similar to those of the phase III by Belani which also compared carboplatin plus weekly paclitaxel with carboplatin plus standard paclitaxel although most patients were <70 years old and the dose of weekly paclitaxel (100 mg/m 2 /week) and the additional maintenance therapy of paclitaxel were different from our study. More than half of the patients included in our study were >75 years old which is similar to the population of elderly patients in general practice. Thus, we believe, at least for patients with good PS, the platinum doublet regimen is a reasonable choice even if they are >75 years old. Regarding the toxic effects, the incidence of grade 3/4 neutropenia and febrile neutropenia in the patients of the W arm was apparently lower than that in the patients of the S arm. The peripheral neuropathy observed in the patients of the W arm was also significantly mild and manageable as compared with that in the patients of the S arm. The results of the efficacy and safety of the present regimen comprising weekly paclitaxel were comparable to those observed in our previous study and other studies [8-10, 15, 17] . Its safety profile, in particular, is the greatest strength that may benefit elderly patients with less tolerance to chemotherapy. Recently, Ramalingam et al. [18] reported the results of subset analysis from Belani's study specifically targeted for elderly population. Very similar to our study, they also concluded that regimen with weekly paclitaxel was equally effective and less toxic than that with standard paclitaxel in the elderly population, although the response rate of weekly regimen was less than that in our study (26% versus 55%). There are also some differences in toxic effects between the weekly regimens of each study. For example, incidences of grade 3 neuropathy, grade 3 or worse neutropenia, and anemia were 5.5%, 17%, and 16%, respectively, in Ramalingam study; meanwhile, those incidences in our study were 0%, 41%, and 29%, respectively. As to the neuropathy, dosage of paclitaxel and the maintenance therapy might have influenced the result. On the other hand, the difference of hematological toxic effects might depend on some genetic difference between USA and Japanese patients because recent large common-arm analysis between United States and Japan revealed that Japanese patients suffered from significantly higher hematological toxic effects than USA patients even if treated with similar dose of paclitaxel and carboplatin [19] . The present study has a few limitations. The first limitation is that since the sample size used in this study was small, a definitive conclusion cannot be reached solely on the basis of the findings of this study. However, previous reports support the results obtained for each treatment conducted in this study. Since it is still unclear as to which of the two strategies of platinum doublet chemotherapy and single-agent chemotherapy is superior to the other, a larger comparative study should be conducted in future. We believe that the weekly paclitaxel and carboplatin combination used in this study may be a successful candidate as a proper platinum doublet regimen. The second limitation of this study is that we did not conduct a comprehensive geriatric assessment (CGA) or assess the quality of life of the patients in this study. The difficulty in the treatment of elderly patients is due to the heterogeneity of their comorbidities and organ functions. CGA has been recognized as a very important tool for the evaluation of the general conditions of the elderly patients; this tool must be applied in future trials for the identification and selection of a heterogeneous elderly population [20, 21] . And finally, the superiority between platinum doublet and single-agent chemotherapy in elderly population remains unclear; thus, we are now conducting the next randomized study comparing the current weekly paclitaxel with carboplatin to docetaxel alone.
In conclusion, this is the first randomized study that analyzed the efficacy and safety of the platinum doublet chemotherapy specifically designed for the elderly. In this study, the efficacy of both the treatment regimens consisting of paclitaxel and carboplatin was similar. Regarding the safety, the regimen comprising weekly paclitaxel was less toxic than that with the standard paclitaxel dosage and seems to be preferable for elderly patients with advanced NSCLC and is worthy of further investigation.
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